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Abstrak 
Selective serotonin re-uptake inhibitors (SSRIs) merupakan golongan antidepresan yang cukup selektif terhadap 
serotonin re-uptake transporter (SERT). Sertraline dan fluoxetine merupakan golongan SSRI yang mempunyai 
afinitas kuat terhadap SERT serta mampu menghambat neurotransmitter recycling. Akan tetapi, kedua obat 
tersebut juga mempunyai afinitas terhadap norepinephrine and dopamine transporter (NAT dan DAT) yang 
menyebabkan terjadinya efek samping. Oleh karena itu, penelitian mengenai interaksi antara SSRI dan SERT 
sangat penting untuk mengetahui faktor penentu interaksi obat-reseptor. Penggunaan Leucine Transporter 
(LeuT), model SERT yang berasal dari bakteri Aquifexaeolicus, bisa menjelaskan interaksi SSRI-SERT. Akan 
tetapi, karena perbedaan spesiesasal reseptor, obat yang efektif pada LeuT belum tentu efektif pada SERT. 
Penggunaan LeuT bisa menjelaskan interaksi SSRIs-SERT secara molekuler. Halogen binding pocket (HBP) 
merupakan faktor penentu dalam interaksi SSRI-SERT. LeuT memiliki~25% sekuen yang sama dengan SERT 
pada manusia. Konservasi pada sekuen ini ditemukan pada sisi aktif reseptordimana HPB berada. LeuT sebagai 
reseptor model mampu menggambarkan interaksi antara obat dan reseptor. Hasil penemuan tersebut sangat 
bermanfaat untuk pengembangan obat antidepresan yang lebih selektif. (Health Science Indones 2010; 1: 51 - 
57) 
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Abstract 
Selective serotonin re-uptake inhibitors (SSRIs) have been considered to be promising drugs in psychiatric 
practice because of their selectivity to serotonin re-uptake transporter (SERT). Sertraline and fluoxetine are 
considered to be effective SSRIs as their ability in binding SERT and inhibit neurotransmitter recycling. However, 
they also bind norepinephrine and dopamine transporter (NAT and DAT) that cause undesirable effects. Thus, the 
study of drug-receptor interaction between SSRIs and SERT is important to gauge the active site of the drugs. By 
using Leucine Transporter (LeuT) from Aquifexaeolicusas a SERT model, the mode of SSRIs-SERT interaction 
was revealed. Nonetheless, it is uncertain whether the drugs that bind to LeuT would be effective to human SERT 
because of the high evolutionary convergence between them. Halogenbinding pocket (HBP) was found to be the 
key determinant in the drug-receptor interaction. LeuT has ~25% sequence similarity to human SERT with highly 
conserved amino acid sequences in the active site of these receptors, in which HBP is located. LeuT as the 
receptor model revealed the interaction between drugs and receptors. All these findings are very useful to develop 
more selective antidepressant medicines. (Health Science Indones 2010; 1: 51 - 57) 
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Structural studies of drugs and receptors 
interaction have disclosed the mechanism of 
action of the drugs. Molecular study is also 
useful in drug development to define a 
particular feature that plays a role in the drug 
and receptor interaction. By using this 
knowledge, a new drug could be directed 
towards a better efficacy and safety.  
The discovery of selective serotonin re-uptake 
inhibitors (SSRIs) have emerged therapeutic 
advance in neuropsychopharmacology.  SSRIs 
are effective antidepressantsthat have high 
selectivity to the receptors.
1
SSRIs act as 
antidepressant by slowing the removal of  
serotonin.
2  
By maintaining serotonin balance in 
the brain, SSRIs help relieve the symptoms of 
depression.
3  
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Compared to tricyclic anti-depressant (TCA) 
and monoamine oxidase (MAO) inhibitors, 
SSRIs have a better selectivity as they only act 
on the neurotransmitter serotonin. Thus, they 
have fewer side effects than TCA and MAO 
inhibitors. The side effects of SSRIs may 
include dry mouth, nausea, nervousness, 
insomnia, drowsiness, weakness, uncontrollable 
shaking of a part of the body, loss of appetite, 
weight loss, headache, excessive sweating and 
sexual problems.
4 
Sertraline and fluoxetine are 
SSRIs drugs broadly used recently as the first 
line of treatment for depressive disorders.
5
 
The effect of SSRIs is achieved by inhibition of 
the presynaptic plasma membrane serotonin re-
uptake transporter (SERT).
1,6  
SERT is located 
in the neural plasma membrane. Serotonin is 
mainly inactivated by a reuptake to the pre-
synaptic plasma membrane through SERT. 
Thus, SERT plays an important role in pre-
synaptic neurotransmission.
2 
Consequently 
SERT is a suitable target for further anti-
depressant development.
7
 
X-ray crystallography is a very useful technique 
to demonstrate the interaction between drugs 
and receptors. However, not every protein can 
be crystallized. In this case, human SERT is 
technically difficult to be crystallized.
8 
Therefore, many studies tried to find the most 
appropriate SERT model. To facilitate the 
study, a model protein derived from a bacterial 
cell (Aquifexaeolicus), named leucine 
transporter model (LeuT) has been used 
recently.
1
 
As LeuT protein is derived from bacteria; it 
raises questions regarding the effectiveness of 
the drug for a real application in human. 
Therefore, it is important to know the similarity 
of this model with human SERT, especially in 
their key determinant regions. The objective of 
this article is to review the key determinant of 
the drug-receptor interaction and to gauge the 
similarity between LeuT and SERT. 
Structure and function analysis of LeuT-
SSRI protein 
A study utilized X-ray crystallography shows 
the interaction of a bacterial LeuT protein in 
complex with three different SSRIs (sertraline, 
R-fluoxetine and S-fluoxetine). The molecular 
structure were generated with PyMOL.
1
 
 
   
a b c 
Figure 1. LeuT in complex with sertraline (a), R-fluoxetine (b) and S-fluoxetine (c).1 
 
Sertraline, R-fluoxetine and S-fluoxetine have 
same features in their interaction with LeuT. 
Based on the molecular complexes (Figure 1), it 
is shown that the drugs bound several similar 
amino acid residues although they do not share 
the same physical space.
1 
Sertraline structure 
consists of two chlorine atoms attached to one 
of the aromatic rings, while fluoxetine structure 
has three fluoride atoms attached to one of the 
aromatic rings.
9 
Notably, the halogen atoms at 
phenyl rings of SSRIs bind to LeuT at the same 
position.
1
 These features suggest that SSRIs 
may also bind to human SERT in the same way 
at similar positions.  
The location in which halogen atoms interact 
with LeuT molecule, named halogen-binding 
pocket (HBP), is the key determinant of the 
antidepressant drug receptors.
1
 This result is 
supported by another study that shows the 
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importance of Cl
-
 in fluoxetine for affinity to 
SERT. The chorine atoms affect the forming of 
appropriate conformation to achieve to most 
optimal binding to SERT.
10 
Therefore, the 
halogen atoms in SSRIs should be retained in 
further development of the drugs. 
The amino tails of sertraline and R-fluoxetine 
point toward the cytoplasm and interact with 
Gln34 by binding a water molecule (Figure 
1.a,b.). The complex of sertraline binds to LeuT 
was formed by interaction of two chlorine 
atoms on the aromatic ring insert to HBP within 
the LeuT molecule. Similarly, R and S-
fluoxetine insert their fluoride atoms in the 
HBP (Figure 1.a, 1.b, 1.c.). The HBP is located 
in the EL4 hairpin loop and enclosed by Leu25, 
Gly26, Leu29, Arg30, Tyr108, Ile111 and 
Phe253. Four of these amino acid residues, 
which are Leu25, Gly26, Tyr108 and Phe253, 
interact with a substrate leucine at the opposite 
side of the polypeptide chain. The drug-binding 
site and the substrate-binding site share several 
amino acid residues although they interact at 
the opposite side. The other part of the drugs 
might interact with LeuT in various ways, but 
the interaction of LeuT to halogen atoms 
remains unchanged.
1
 
Bioinformatics analysis of human SERT and 
LeuT from bacteria Aquifexaeolicus 
Bioinformatics analysis was performed to 
observe homology between LeuT and human 
SERT. This approach utilized Pfam database 
and bioinformatics study from other related 
papers.  
Global alignment of human SERT and LeuT 
Since human SERT and LeuT from bacteria 
Aquifexaeolicus derived from different species 
with high evolutionary convergence, global 
alignment was chosen as the most suitable way 
to find their sequence similarity. The alignment 
(Figure 2) results in ~25% similarity between 
them. There are many gaps in the alignment. 
This probably caused by the different size of 
the gene encoding transporters.  
 
 
Figure 2. Alignment of human SERT and LeuT resulted from global alignment/Clustal W by using Pfam 
database.
14 
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Protein domains of LeuT from Aquifex-
aeolicus and human SERT in PFam 
Human SERT and LeuT domains were observed 
in UniProt database. From the result, it is shown 
that human SERT have 5-HT transporter and 
sodium neurotransmitter symporter family 
(SNF) (Figure 3 and 4). 
 
 
 
 
Figure 3 Human SERT domains.
14 
 
 
 
 
Figure 4 LeuT domains.
14 
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Both human SERT and LeuT have SNF 
domains although in LeuT it is smaller and also 
fragmented. It might be because LeuT has a 
smaller size of gene encoding the receptor 
compared to SERT. However, it could represent 
the possibility of the drugs to bind the similar 
domains.  
The transport function of SERT is determined 
by the structure of an oligomeric protein with 
disulfide bridges between cystein residues. It 
has 12 transmembrane-helices (TMH) 
domains that transport serotonin together with 
sodium and chloride ions.
2,12
 It also has amino 
and carboxy termini and a large extracellular 
loop at which N-linked glycosylation sites were 
attached.
13
 
A crystallography study showed that LeuT also 
has 12 TMH, which is similar to that of human 
SERT. Hence, LeuT has been used for model 
system to study human NSS (neurotransmitter 
sodium symporter).
14
 
Conservation between SERT, LeuT, DAT 
and NET 
SERT has certain similarities to other 
Neurotransmitter Sodium Symporter (NSS), 
which are Norepinephrine Transporter 
(NET)and Dopamin Transporter (DAT). 
Sequence alignment between SERT, LeuT, 
DAT and NET in the previous study indicates 
conservation between them.  Conservation of 
amino acid sequence in the halogen-binding 
pocket is important in maintaining the receptor 
functions. The only key difference in region 
EL4 is that SERT possesses a glycine residue at 
position 100 while NET and DAT possess 
alanin residue. According to the mutagenesis 
assay continued by binding assay, mutation at 
this glycine into alanin inhibited transport 
activity of SERT.
1
This indicates that glycine 
plays an important role in SERT specificity to 
SSRIs. In contrast, mutation of an alanin residue 
in NET and DAT to a glycine resulted in the 
increase of binding affinity to SSRIs. The result 
suggests that SERT is more specific to SSRIs 
compared to NET and DAT. Compared to NET 
and DAT, SSRIs have a better binding affinity 
to SSRIs.
1 
Multiple sequence alignment between human 
NSS (SERT, NET and DAT) and LeuT that was 
conducted by another study showed 
evolutionary conservation between them. Those 
results were achieved by using ICM homology 
modeling.
15
 Based on this homology study 
combined with computational study, the 
structural models for the three NSS have been 
elucidated (Figure 5). 
 
   
a b c 
Figure 5. Structural model of human NSS utilized LeuT. a. SERT model, b. DAT model, c. NET 
               model.
15 
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Those structural model shows similarity of 
molecular structure between SERT, DAT and 
DET. They also have similar characteristic in 
their way forming a dipole moment that leads 
them being more negative towards the 
extracellular side.
15 
The previous study 
elucidated sequence similarity of those 
receptors specifically in the EL4 hairpin loop 
position (Table 1).
1
 
 
 
 
Table 1. Sequence comparison of four NSS proteins in EL4 hairpin loop position
1 
 
LeuT SERT NET DAT 
Leu25 Leu99 Leu76 Leu80 
Gly26 Gly100 Ala71 Ala81 
Leu29 Trp103 Trp80 Trp84 
Arg30 Arg104 Arg81 Arg85 
Tyr108 Tyr176 Tyr151 Tyr156 
Ile111 Ile179 Ile155 Ile159 
Phe253 Phe335 Phe317 Phe320 
 
The only difference between amino acid 
sequence of LeuT and SERT in this region is 
tryptophan (Trp103), which is leucine (Leu29) 
in LeuT (Table 1). However, there is no other 
data regarding this feature. It is unknown 
whether this difference feature would affect the 
interaction and function of the receptors or not. 
Thus, it would be better if this feature were also 
observed to ascertain the similarity between 
LeuT and SERT.  
A subsequent study found that homology of 
LeuT and SERT is optimal between 
transmembrane domains (TMDs) region. Also, 
it was found that the binding site for the 
substrates (either leucine or serotonine) as well 
as Na
+ 
and Cl
-
 indicates similar kinetics and 
structural properties.
16 
Therefore, LeuT 
represents a reliable template to model SERT 
protein. 
In conclusion, based on the alignment results, 
LeuT has low similarity to human SERT, which 
is only ~25%. But, the amino acid sequences are 
highly conserved in the active site of these 
receptors, in which the HBP is located. 
Mutagenesis and binding assay study proved 
that their conservation is important for the 
receptor function in transporting serotonin. 
Additionally, LeuT has similar conformation 
with human SERT. All these suggest that LeuT 
is appropriate to represent human SERT in 
binding SSRIs. 
The specificity of SERT bind to SSRIs is very 
important in defining the key feature that has to 
be retained in further development of 
antidepressants. HBP is the key determinant of 
SSRIs-SERT interaction. The halogen atoms 
play an important role in the drug-receptor 
binding. Thus, the halogen atoms should be 
retained in further antidepressant development.  
As SSRIs have low binding affinity to NET and 
DAT and this interaction causes side effects, 
further study should be directed to eliminate this 
undesired interaction. Furthermore, a particular 
study regarding interaction of SSRIs and NET 
as well as DAT is required in order to know the 
key feature that should be eliminated to avoid 
their interaction. 
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